Profil
Romuald Corbau worked as Chief Scientific Officer at Freeline Therapeutics Holdings Ltd. from 2020 to 2021.
Dr. Corbau worked as Chief Scientific Officer at GenEdit, Inc. Dr. Corbau worked as Chief Scientific Officer at Adverum Biotechnologies, Inc. from 2024 to 2025.
Dr. Corbau graduated from Université des Sciences et Technologies de Lille.
Anciens postes connus de Romuald Corbau
| Sociétés | Poste | Fin |
|---|---|---|
| ADVERUM BIOTECHNOLOGIES, INC. | Directeur Technique/Scientifique/R&D | 09/12/2025 |
| FREELINE THERAPEUTICS HOLDINGS PLC | Directeur Technique/Scientifique/R&D | 20/08/2021 |
GenEdit, Inc.
GenEdit, Inc. BiotechnologyHealth Technology Develops next generation therapeutics for genetic diseases | Directeur Technique/Scientifique/R&D | - |
Formation de Romuald Corbau
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Université des Sciences et Technologies de Lille
Université des Sciences et Technologies de Lille Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and sells novel gene therapies | Health Technology |
GenEdit, Inc.
GenEdit, Inc. BiotechnologyHealth Technology Develops next generation therapeutics for genetic diseases | Health Technology |
Freeline Therapeutics Holdings Plc
Freeline Therapeutics Holdings Plc BiotechnologyHealth Technology Develops and manufactures next-generation gene therapies | Health Technology |
















